Study of ANAVEX2-73 in Patients With Rett Syndrome
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized,
placebo-controlled study.
7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients
with RTT 18 years or older. A voluntary option will be offered for all patients who meet the
exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.
Phase:
Phase 2
Details
Lead Sponsor:
Anavex Life Sciences Corp.
Collaborator:
International Rett Syndrome Foundation Rettsyndrome.org